DURHAM, N.C., July 1, 2015 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat" or the "Company") (Nasdaq:HTBX), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, today announced that Jeff Wolf, CEO, will present a corporate update at the Cantor Fitzgerald Healthcare Conference in New York City on July 8.
|Cantor Fitzgerald Inaugural Healthcare Conference|
|Date:||Wednesday, July 8|
|Time:||8:00am Eastern Time|
About Heat Biologics, Inc.
Heat Biologics, Inc. (www.heatbio.com) is a clinical-stage biopharmaceutical company focused on developing its novel, "off-the-shelf" ImPACT™ therapeutic vaccines to combat a wide range of cancers. Our ImPACT™ Therapy is designed to deliver live, genetically-modified, irradiated human cells which are reprogrammed to "pump out" a broad spectrum of cancer-associated antigens together with a potent immune adjuvant called "gp96" to educate and activate a cancer patient's immune system to recognize and kill cancerous cells. Heat is conducting a Phase 2 trial of its viagenpumatucel-L (HS-110) in patients with non-small cell lung cancer as well as a Phase 2 trial with its vesigenurtacel-L (HS-410) in patients with non-muscle invasive bladder cancer.
CONTACT: Heat Biologics, Inc. Jeff Wolf Chief Executive Officer 919-240-7133 firstname.lastname@example.org Investor Relations & Media Inquiries Michael Wood LifeSci Advisors, LLC 646-597-6983 mwood@LifeSciAdvisors.com